Prometheus Biosciences, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mark C. McKenna
- Full Time Employees
- 97
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9410 Carroll Park Drive San Diego CA United States of America 92121
- IPO Date
- Mar 12, 2021
- CIK
- 0001718852
- Website
- prometheusbiosciences.com
- Similar Companies
- Business
- Prometheus Biosciences, Inc. (RXDX), founded in 2016 and headquartered in San Diego, California, discovers, develops, and commercializes novel precision therapeutics and companion diagnostics for immune-mediated diseases, with a primary focus on inflammatory bowel disease (IBD) including ulcerative colitis and Crohn's disease; its lead product candidate is PRA023 (now MK-7240 following acquisition), a humanized monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A) associated with intestinal inflammation and fibrosis, currently advancing in clinical trials for ulcerative colitis, Crohn's disease, systemic sclerosis-associated interstitial lung disease, and other autoimmune conditions; the company leverages its proprietary Prometheus360 platform, which integrates machine learning with extensive patient data from genetics, serologics, transcriptomics, and longitudinal clinical outcomes to identify drug targets and biomarkers. Prometheus operates in the biotechnology sector, serving patients and healthcare providers worldwide through its precision medicine approach to gastroenterology and immunology. In June 2023, Merck & Co., Inc. completed its $10.8 billion acquisition of Prometheus, making it a wholly-owned subsidiary delisted from Nasdaq, thereby integrating PRA023 and additional pipeline assets including PR600, PR300, PR1100, PR1800, and PR2100 into Merck's immunology portfolio to accelerate development and commercialization.
Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus deal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXDX, MDWT, RUTH
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDX
Why Prometheus Biosciences Stock Is Skyrocketing This Week
Why Merck Is Buying Prometheus Biosciences For About $10.8 Billion
Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?
Roivant Sciences shares spike on Merck-Prometheus Biosciences deal
Merck's Prometheus Acquisition Is A Step In The Right Direction
Why Shares of Prometheus Biosciences Are Soaring Monday
Biotech stock Prometheus Biosciences opened 70% up today: here's why
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging Today
Merck's $10.8 Billion Prometheus Deal Has Citi Analysts Bullish
Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?
Prometheus Biosciences, XPeng and State Street are among the stocks on the move
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.